Biotech News Brief

Biotech news for Saturday, August 1, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.

Watchlist · 65/100Jul 30, 12:55 PM EDT

Vericel Raises 2026 Outlook to $330M-$340M and Unveils $200M Buyback

VCEL

Vericel (VCEL) reported record Q2 2026 revenue of over $77 million, up 22% year-over-year, and raised its full-year 2026 revenue guidance to $330 million-$340 million. The company also announced a $200 million share repurchase program, signaling confidence in…

  • Strong revenue growth and raised guidance indicate commercial success.
  • Share repurchase program signals confidence but no major pipeline catalysts.